



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021,
please refer to the [EMA](#) website.

Suvaxyn PRRS MLV Lyophilisate and Solvent for Suspension for Injection for Pigs Vm 42058/5075

•	28 July 2023	To include the nasal route as an additional administration route for the product.
•	28 July 2023	Modifications of indications in section 4.2 and section 5 of the SPC and in section 4 and section 15 of the leaflet, respectively, related to cross-protection against the virulent heterologous PRRSV -1 field strains (AUT15-33, BOR57 and Lena).
•	12 May 2023	Replacement of the media used for early stages of cell culture during antigen production.
•	17 April 2023	Addition of a secondary packaging site for the finished product. Addition of a secondary packaging site for the finished product.
•	27 February 2023	To include Lincoln site in the USA as an alternative site for preparation, testing and storage of new WCS for Suvaxyn PRRS MLV vaccine.
•	16 November 2022	Addition of Denmark, France, Germany and the Netherlands as a source of porcine pancreas used for the production of trypsin.
•	22 April 2022	Renewal